Allianz Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Allianz Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12,049	Closed	-$450K	–	2697
2021 Q2	$450K	Buy	+12,049	New	+$369K	﹤0.01%	2086
2020 Q3	–	Sell	-8,290	Closed	-$210K	–	2485
2020 Q2	$210K	Sell	8,290 -112,008	-93%	-$2.41M	﹤0.01%	2285
2020 Q1	$2.21M	Sell	120,298 -49,712	-29%	-$966K	﹤0.01%	1487
2019 Q4	$3.75M	Sell	170,010 -36,627	-18%	-$737K	﹤0.01%	1613
2019 Q3	$3M	Buy	206,637 +28,425	+16%	+$406K	﹤0.01%	1663
2019 Q2	$2.81M	Buy	178,212 +78,015	+78%	+$1.06M	﹤0.01%	1756
2019 Q1	$1.47M	Sell	100,197 -10,937	-10%	-$126K	﹤0.01%	1955
2018 Q4	$1.19M	Buy	111,134 +86,567	+352%	+$1.14M	﹤0.01%	1957
2018 Q3	$375K	Buy	+24,567	New	+$358K	﹤0.01%	2440

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Allianz Asset Management's DRNA Position: Q3 2021 in Review

Allianz Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 12,049 shares — an estimated $450K sold.

Allianz Asset Management first reported a position in DRNA in Q3 2018 and held it in 9 quarters. The position peaked at $3.75M in Q4 2019. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Allianz Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Allianz Asset Management sold 12,049 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $450K.
Allianz Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2018 and held it in 9 quarters.
Allianz Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $3.75M in Q4 2019.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Allianz Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.